Richard Francis appointed CEO of Teva Pharmaceutical

Sunday 4 December 2022
Teva Pharmaceutical Industries Ltd
Appointee name
Richard Francis


Richard Francis, a former Novartis executive, has been appointed chief executive of Teva Pharmaceutical Industries Ltd, effective 1 January 2023, succeeding Kåre Schultz who is retiring. Mr Francis will be joining from Purespring Therapeutics Ltd which is developing gene therapies for chronic renal diseases. He has also served as CEO of Sandoz, the Novartis generic and biosimilar division, and was a member of the Novartis executive team. Based in Israel, Teva has a portfolio of more than 3,500 products including generic, biosimilar and specialty medicines.

Teva announced the appointment on 21 November 2022.

Copyright 2022 Evernow Publishing Ltd